JP2017507670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507670A5 JP2017507670A5 JP2016570934A JP2016570934A JP2017507670A5 JP 2017507670 A5 JP2017507670 A5 JP 2017507670A5 JP 2016570934 A JP2016570934 A JP 2016570934A JP 2016570934 A JP2016570934 A JP 2016570934A JP 2017507670 A5 JP2017507670 A5 JP 2017507670A5
- Authority
- JP
- Japan
- Prior art keywords
- pgf2
- composition
- pacap
- derivatives
- sdf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 claims description 38
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 claims description 38
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 claims description 38
- 239000003446 ligand Substances 0.000 claims description 36
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 26
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 24
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims description 24
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 24
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 24
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 24
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims description 24
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims description 14
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims description 14
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 claims description 14
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 12
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 claims description 12
- PXGPLTODNUVGFL-ZWAKLXPCSA-N 11-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-ZWAKLXPCSA-N 0.000 claims description 12
- RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 claims description 12
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 12
- 102000013585 Bombesin Human genes 0.000 claims description 12
- 108010051479 Bombesin Proteins 0.000 claims description 12
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 12
- 108090000312 Calcium Channels Proteins 0.000 claims description 12
- 102000003922 Calcium Channels Human genes 0.000 claims description 12
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 12
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 12
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 12
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims description 12
- 102000004889 Interleukin-6 Human genes 0.000 claims description 12
- 108090001005 Interleukin-6 Proteins 0.000 claims description 12
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 12
- 102000004257 Potassium Channel Human genes 0.000 claims description 12
- 102000001708 Protein Isoforms Human genes 0.000 claims description 12
- 108010029485 Protein Isoforms Proteins 0.000 claims description 12
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 claims description 12
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 claims description 12
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 claims description 12
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 claims description 12
- ZCDNRPPFBQDQHR-SSYATKPKSA-N Syrosingopine Chemical compound C1=C(OC)C(OC(=O)OCC)=C(OC)C=C1C(=O)O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@H]2C[C@@H]3C(NC=4C5=CC=C(OC)C=4)=C5CCN3C[C@H]2C1 ZCDNRPPFBQDQHR-SSYATKPKSA-N 0.000 claims description 12
- 102000004243 Tubulin Human genes 0.000 claims description 12
- 108090000704 Tubulin Proteins 0.000 claims description 12
- 229930013930 alkaloid Natural products 0.000 claims description 12
- 239000005557 antagonist Substances 0.000 claims description 12
- 230000002973 anti-dopamine Effects 0.000 claims description 12
- 229940125715 antihistaminic agent Drugs 0.000 claims description 12
- 239000000739 antihistaminic agent Substances 0.000 claims description 12
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229960001338 colchicine Drugs 0.000 claims description 12
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 12
- 229960000616 diflunisal Drugs 0.000 claims description 12
- 229960001342 dinoprost Drugs 0.000 claims description 12
- 239000002804 dopamine agent Substances 0.000 claims description 12
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 12
- 229960001596 famotidine Drugs 0.000 claims description 12
- 229960003580 felodipine Drugs 0.000 claims description 12
- 229930003935 flavonoid Natural products 0.000 claims description 12
- 150000002215 flavonoids Chemical class 0.000 claims description 12
- 235000017173 flavonoids Nutrition 0.000 claims description 12
- 229940100601 interleukin-6 Drugs 0.000 claims description 12
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 12
- 235000008777 kaempferol Nutrition 0.000 claims description 12
- 229940041616 menthol Drugs 0.000 claims description 12
- 229960003632 minoxidil Drugs 0.000 claims description 12
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims description 12
- 108020001213 potassium channel Proteins 0.000 claims description 12
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims description 12
- 229960003081 probenecid Drugs 0.000 claims description 12
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 claims description 12
- 229960003147 reserpine Drugs 0.000 claims description 12
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 229950006534 syrosingopine Drugs 0.000 claims description 12
- XCTYLCDETUVOIP-UHFFFAOYSA-N thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 claims description 12
- 229960004869 thiethylperazine Drugs 0.000 claims description 12
- 230000001052 transient effect Effects 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 9
- 102100033939 Solute carrier family 2, facilitated glucose transporter member 4 Human genes 0.000 claims description 8
- 102000003684 fibroblast growth factor 13 Human genes 0.000 claims description 8
- 108090000047 fibroblast growth factor 13 Proteins 0.000 claims description 8
- 208000030159 metabolic disease Diseases 0.000 claims description 8
- 210000002027 skeletal muscle Anatomy 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 229940123208 Biguanide Drugs 0.000 claims description 6
- 206010022489 Insulin Resistance Diseases 0.000 claims description 6
- 102000002512 Orexin Human genes 0.000 claims description 6
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 claims description 6
- 239000000048 adrenergic agonist Substances 0.000 claims description 6
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims description 6
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 claims description 6
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims description 6
- 150000004283 biguanides Chemical class 0.000 claims description 6
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 6
- 229960003105 metformin Drugs 0.000 claims description 6
- OHOWSYIKESXDMN-WMQZXSDYSA-N orexin-b Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)C1=CNC=N1 OHOWSYIKESXDMN-WMQZXSDYSA-N 0.000 claims description 6
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims description 6
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 6
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 claims description 6
- 229960000529 riociguat Drugs 0.000 claims description 6
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 claims description 6
- 229950001675 spiperone Drugs 0.000 claims description 6
- 208000004930 Fatty Liver Diseases 0.000 claims description 5
- DGFYECXYGUIODH-UHFFFAOYSA-N Guanfacine hydrochloride Chemical compound Cl.NC(N)=NC(=O)CC1=C(Cl)C=CC=C1Cl DGFYECXYGUIODH-UHFFFAOYSA-N 0.000 claims description 5
- 229960004746 guanfacine hydrochloride Drugs 0.000 claims description 5
- VSWSDTLXDWESGZ-AWEZNQCLSA-N (2s)-3-[4-(4-hydroxyphenoxy)phenyl]-2-(iodoamino)propanoic acid Chemical compound C1=CC(C[C@@H](C(=O)O)NI)=CC=C1OC1=CC=C(O)C=C1 VSWSDTLXDWESGZ-AWEZNQCLSA-N 0.000 claims description 4
- 102100039660 Adenylate cyclase type 4 Human genes 0.000 claims description 4
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 claims description 4
- 108050008792 Atypical chemokine receptor 3 Proteins 0.000 claims description 4
- 102100034159 Beta-3 adrenergic receptor Human genes 0.000 claims description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 208000032841 Bulimia Diseases 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- 102000053028 CD36 Antigens Human genes 0.000 claims description 4
- 108010045374 CD36 Antigens Proteins 0.000 claims description 4
- 102100032141 Cell death activator CIDE-A Human genes 0.000 claims description 4
- 102100032051 Elongation of very long chain fatty acids protein 3 Human genes 0.000 claims description 4
- 208000017701 Endocrine disease Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108010001387 Fatty Acid-Binding Protein 7 Proteins 0.000 claims description 4
- 102000002140 Fatty Acid-Binding Protein 7 Human genes 0.000 claims description 4
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 claims description 4
- 102100024233 High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Human genes 0.000 claims description 4
- 101000959333 Homo sapiens Adenylate cyclase type 4 Proteins 0.000 claims description 4
- 101000921367 Homo sapiens Elongation of very long chain fatty acids protein 3 Proteins 0.000 claims description 4
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 claims description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 201000001431 Hyperuricemia Diseases 0.000 claims description 4
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 claims description 4
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 108050000742 Orexin Receptor Proteins 0.000 claims description 4
- 206010036049 Polycystic ovaries Diseases 0.000 claims description 4
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 4
- 108091006300 SLC2A4 Proteins 0.000 claims description 4
- 102100030058 Secreted frizzled-related protein 1 Human genes 0.000 claims description 4
- 101710104321 Solute carrier family 2, facilitated glucose transporter member 4 Proteins 0.000 claims description 4
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims description 4
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims description 4
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 4
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 4
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 4
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 4
- 230000011759 adipose tissue development Effects 0.000 claims description 4
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 claims description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 4
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 claims description 4
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 claims description 4
- 102100024232 cAMP-specific 3',5'-cyclic phosphodiesterase 7B Human genes 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 4
- 201000008980 hyperinsulinism Diseases 0.000 claims description 4
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 229940072041 transforming growth factor beta 2 Drugs 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 150000004669 very long chain fatty acids Chemical class 0.000 claims description 4
- 208000030172 endocrine system disease Diseases 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 2
- 101710196996 Cell death activator CIDE-A Proteins 0.000 claims description 2
- 101710111837 Cyclic phosphodiesterase Proteins 0.000 claims description 2
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 2
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101710133689 High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Proteins 0.000 claims description 2
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 claims description 2
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 2
- 101000775570 Homo sapiens Cell death activator CIDE-A Proteins 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 101001117267 Homo sapiens High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Proteins 0.000 claims description 2
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 claims description 2
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 2
- 101001117266 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 7B Proteins 0.000 claims description 2
- 206010062767 Hypophysitis Diseases 0.000 claims description 2
- 208000003351 Melanosis Diseases 0.000 claims description 2
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 claims description 2
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 claims description 2
- 102000000536 PPAR gamma Human genes 0.000 claims description 2
- 108091008767 PPARγ2 Proteins 0.000 claims description 2
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 claims description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 2
- 102100026155 Transcription factor A, mitochondrial Human genes 0.000 claims description 2
- 101710106416 Transcription factor A, mitochondrial Proteins 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 108060000200 adenylate cyclase Proteins 0.000 claims description 2
- 102000030621 adenylate cyclase Human genes 0.000 claims description 2
- 210000003486 adipose tissue brown Anatomy 0.000 claims description 2
- 210000000593 adipose tissue white Anatomy 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims description 2
- 210000001593 brown adipocyte Anatomy 0.000 claims description 2
- 101710089481 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 claims description 2
- 101710087525 cAMP-specific 3',5'-cyclic phosphodiesterase 7B Proteins 0.000 claims description 2
- 238000005831 deiodination reaction Methods 0.000 claims description 2
- 238000003795 desorption Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 230000002631 hypothermal effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000037323 metabolic rate Effects 0.000 claims description 2
- 230000001483 mobilizing effect Effects 0.000 claims description 2
- 210000003635 pituitary gland Anatomy 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims 3
- 108060005714 orexin Proteins 0.000 claims 2
- 208000012185 Alzheimer disease 11 Diseases 0.000 claims 1
- 208000012301 Alzheimer disease 6 Diseases 0.000 claims 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 claims 1
- 229960002048 guanfacine Drugs 0.000 claims 1
- 239000000463 material Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- -1 isoform SDF-1γ Chemical compound 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461966496P | 2014-02-24 | 2014-02-24 | |
| US61/966,496 | 2014-02-24 | ||
| PCT/US2015/017392 WO2015127474A1 (en) | 2014-02-24 | 2015-02-24 | Methods and compositions for inducing differentiation of human brown adipocyte progenitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019110252A Division JP2019193639A (ja) | 2014-02-24 | 2019-06-13 | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507670A JP2017507670A (ja) | 2017-03-23 |
| JP2017507670A5 true JP2017507670A5 (cg-RX-API-DMAC7.html) | 2018-03-22 |
Family
ID=53879173
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570934A Pending JP2017507670A (ja) | 2014-02-24 | 2015-02-24 | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 |
| JP2019110252A Pending JP2019193639A (ja) | 2014-02-24 | 2019-06-13 | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 |
| JP2020206597A Active JP7256165B2 (ja) | 2014-02-24 | 2020-12-14 | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 |
| JP2023056276A Pending JP2023073455A (ja) | 2014-02-24 | 2023-03-30 | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019110252A Pending JP2019193639A (ja) | 2014-02-24 | 2019-06-13 | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 |
| JP2020206597A Active JP7256165B2 (ja) | 2014-02-24 | 2020-12-14 | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 |
| JP2023056276A Pending JP2023073455A (ja) | 2014-02-24 | 2023-03-30 | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20220331403A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3943092B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2017507670A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106255748B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015127474A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006283211B2 (en) | 2005-08-22 | 2012-06-21 | Melior Pharmaceuticals I, Inc. | Methods and formulations for modulating Lyn kinase activity and treating related disorders |
| US20130158055A1 (en) | 2010-05-28 | 2013-06-20 | Andrew G. Reaume | Prevention Of Pancreatic Beta Cell Degeneration |
| US20190083574A1 (en) * | 2016-03-29 | 2019-03-21 | Ohio State Innovation Foundation | Thermogenic compositions and methods |
| JP6909569B2 (ja) * | 2016-09-16 | 2021-07-28 | オリザ油化株式会社 | 肌質改善剤 |
| US11357841B2 (en) * | 2017-01-06 | 2022-06-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| CN108619490A (zh) * | 2017-03-22 | 2018-10-09 | 天士力医药集团股份有限公司 | 一种长效化突变的人源成纤维生长因子的新用途 |
| EP3609500B1 (en) * | 2017-04-10 | 2024-11-13 | Melior Pharmaceuticals I, Inc. | Treatment of adipocytes |
| CN109893655B (zh) * | 2017-12-11 | 2021-07-20 | 义慧科技(深圳)有限公司 | miR-327抑制剂和/或FGF10促进剂在预防和/或治疗糖尿病的药物中的应用 |
| CN109893656B (zh) * | 2017-12-11 | 2021-07-20 | 义慧科技(深圳)有限公司 | miR-327抑制剂和/或FGF10促进剂在预防和/或治疗脂肪代谢症药物中的应用 |
| JP2020143008A (ja) * | 2019-03-05 | 2020-09-10 | 達也 楠堂 | 新規褐色脂肪細胞分化誘導剤 |
| CN109820857A (zh) * | 2019-03-27 | 2019-05-31 | 中国科学院广州生物医药与健康研究院 | 化合物dk45的新应用 |
| CN110747163B (zh) * | 2019-11-13 | 2021-06-11 | 暨南大学 | 一种提高人脂肪间充质干细胞成脂分化的方法及其专用培养基 |
| KR102150821B1 (ko) * | 2020-01-22 | 2020-09-03 | 주식회사 에이스바이오메드 | 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제 |
| US20230190689A1 (en) * | 2020-05-11 | 2023-06-22 | Energesis Pharmaceuticals, Inc. | Methods and compositions for inducing brown adipogenesis |
| KR102346790B1 (ko) * | 2021-04-29 | 2022-01-04 | 주식회사 에이스바이오메드 | 콜히친과 메트포르민을 유효성분으로 하는 항비만 치료제 |
| CN114225006B (zh) * | 2021-12-22 | 2023-10-13 | 南京市妇幼保健院 | 一种棕色脂肪细胞分泌肽在低体温疾病防治中的应用 |
| CN115554285A (zh) * | 2022-09-25 | 2023-01-03 | 华北理工大学 | 3-去甲基秋水仙碱在药物中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10330284A (ja) * | 1997-05-30 | 1998-12-15 | Sumitomo Pharmaceut Co Ltd | 肝細胞保護剤 |
| JPH10330285A (ja) * | 1997-05-30 | 1998-12-15 | Sumitomo Pharmaceut Co Ltd | 血糖降下剤 |
| US20050026832A1 (en) * | 1997-11-25 | 2005-02-03 | Genentech, Inc. | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders |
| US6242563B1 (en) * | 1998-07-20 | 2001-06-05 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Peptide analogues |
| AU2003219787A1 (en) * | 2002-02-14 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| CA2522895A1 (en) * | 2003-04-30 | 2004-11-11 | Waratah Pharmaceuticals, Inc. | Combined use of keratinocyte growth factor agonists and gastrin compounds |
| US7576052B2 (en) * | 2003-10-17 | 2009-08-18 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
| US7825098B2 (en) * | 2005-04-04 | 2010-11-02 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating Necdin function |
| WO2006130690A2 (en) * | 2005-06-01 | 2006-12-07 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| CN102083969A (zh) * | 2008-05-06 | 2011-06-01 | 乔斯林糖尿病中心股份有限公司 | 诱导褐色脂肪形成的方法和组合物 |
| AU2009258206B2 (en) * | 2008-05-27 | 2015-07-30 | Energesis Pharmaceuticals, Inc. | Brown adipocyte progenitors in human skeletal muscle |
| FR2932818B1 (fr) * | 2008-06-23 | 2015-12-04 | Centre Nat Rech Scient | Lignee d'adipocytes bruns humains et procede de differenciation a partir d'une lignee de cellules hmads. |
| WO2010011657A1 (en) * | 2008-07-23 | 2010-01-28 | Schering Corporation | Bicyclic heterocycle derivatives as histamine h3 receptor antagonists |
| JP5393119B2 (ja) * | 2008-12-05 | 2014-01-22 | 日本メナード化粧品株式会社 | 幹細胞の褐色脂肪細胞への分化誘導方法 |
| EP2412800A1 (en) * | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| US20110293562A1 (en) * | 2009-02-12 | 2011-12-01 | Proyecto De Biomedicina Cima, S.L. | Use of cardiotrophin-1 for the treatment of metabolic diseases |
| US8916517B2 (en) * | 2009-11-02 | 2014-12-23 | The Administrators Of The Tulane Educational Fund | Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use |
| WO2011126790A1 (en) * | 2010-03-29 | 2011-10-13 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| US20120190615A1 (en) * | 2011-01-20 | 2012-07-26 | Sanford-Burnham Medical Research Institute | Methods and compositions for inducing weight loss |
| AU2012248333B2 (en) * | 2011-04-27 | 2017-05-18 | Id Pharma Co., Ltd. | Pluripotent stem cell-derived brown adipocytes, pluripotent stem cell-derived cell aggregate, method for producing same, and cell therapy and medical therapy therefor |
| EP2709636A2 (en) * | 2011-05-19 | 2014-03-26 | Ariel-University Research and Development Company Ltd. | Use of mesenchymal stem cells for the improvement of affective and cognitive function |
| AU2012335548A1 (en) * | 2011-11-10 | 2014-05-22 | Energesis Pharmaceuticals, Inc. | Brown adipocyte progenitors in human skeletal muscle |
| CN104350146A (zh) * | 2012-03-12 | 2015-02-11 | 新加坡国立大学 | 从间充质细胞制备棕色脂肪组织(bat) |
| AU2013299377A1 (en) * | 2012-08-10 | 2015-02-26 | The Trustees Of Columbia University In The City Of New York | Injectable brown adipose microtissues for treatment and prevention of obesity and diabetes |
| WO2014156462A1 (ja) * | 2013-03-29 | 2014-10-02 | ユーハ味覚糖株式会社 | 白色脂肪細胞の褐色様脂肪細胞分化誘導剤 |
-
2015
- 2015-02-24 JP JP2016570934A patent/JP2017507670A/ja active Pending
- 2015-02-24 WO PCT/US2015/017392 patent/WO2015127474A1/en not_active Ceased
- 2015-02-24 EP EP21193195.1A patent/EP3943092B1/en active Active
- 2015-02-24 EP EP15752698.9A patent/EP3110946B1/en active Active
- 2015-02-24 CN CN201580021132.5A patent/CN106255748B/zh active Active
-
2019
- 2019-06-13 JP JP2019110252A patent/JP2019193639A/ja active Pending
-
2020
- 2020-12-14 JP JP2020206597A patent/JP7256165B2/ja active Active
-
2022
- 2022-06-30 US US17/853,992 patent/US20220331403A1/en not_active Abandoned
-
2023
- 2023-03-30 JP JP2023056276A patent/JP2023073455A/ja active Pending
-
2024
- 2024-08-04 US US18/793,859 patent/US20240382562A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507670A5 (cg-RX-API-DMAC7.html) | ||
| JP7256165B2 (ja) | ヒト褐色脂肪細胞前駆体の分化を誘導するための方法および組成物 | |
| Siddiqui et al. | Physiological bone remodeling: systemic regulation and growth factor involvement | |
| Dore-Duffy | Pericytes: pluripotent cells of the blood brain barrier | |
| KR102066987B1 (ko) | 폴리펩티드 | |
| KR102302634B1 (ko) | 변형된 치료제 및 이의 조성물 | |
| AU2016205311B2 (en) | Factors and cells that provide for induction of bone, bone marrow, and cartilage | |
| JP7617603B2 (ja) | Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子 | |
| CA2976376A1 (en) | Nucleic acid products and methods of administration thereof | |
| JP2010539131A (ja) | アミリンとそのアナログの安定的製剤 | |
| RU2019112897A (ru) | Комбинаторная терапия с агонистами cnp контролируемого высвобождения | |
| ES2690305T3 (es) | Composiciones de Wnt7a y métodos de utilización de las mismas | |
| Kim et al. | An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide | |
| Shao et al. | The cardiac repair benefits of inflammation do not persist: evidence from mast cell implantation | |
| US10150948B2 (en) | Compositions and methods for producing and administering brown adipocytes | |
| US11419916B2 (en) | Methods and compositions for inducing differentiation of human brown adipocyte progenitors | |
| JP6235639B2 (ja) | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 | |
| N. Dube et al. | Thymosin β4 protein therapy for cardiac repair | |
| KR20240135690A (ko) | 절두된 및 융합 단백질 | |
| Edwards et al. | Biochemically engineered stromal cell-derived factor 1-alpha analog increases perfusion in the ischemic hind limb | |
| US20160024249A1 (en) | Temperature-Responsive Polymer Compositions and Methods of Use | |
| WO2019151098A1 (ja) | インスリン産生細胞の製造方法 | |
| Silveira | Fibroblast growth factor and its role in the chondrogenesis of canine mesenchymal stromal cells in three-dimensional collagen scaffolds | |
| Wilson et al. | CXC chemokine receptor signaling in liver repair and regeneration | |
| Hill | PeproTech Inc. |